Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A collaboration between the University of Oxford and Thailand’s Mahidol University has been shortlisted for the prestigious 2017 Newton Prize for its project aiming to understand the early stages of scrub typhus in Thailand.

Jeanne Salje and Nick Day

The Newton Prize is an annual £1 million fund awarded for the best research or innovation that supports the economic development and social welfare of developing countries. Oxford Professor Nick Day is in with the chance of winning up to £200,000 from the Prize to be used to advance or develop the work further.

The project team, headed by Dr Jeanne Salje and Professor Day from Oxford’s Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine and Dr Somponnat Sampattavanich of Mahidol’s Siriraj Department of Pharmacology, has brought together expertise in bacterial cell biology and biochemistry, clinical aspects of scrub typhus and high throughput screening approaches to develop a robust and reproducible high throughput genome wide RNAi imaging screen.

The research has already had a direct impact on scrub typhus clinical work with new methods for bacterial propagation from clinical samples being adopted with improved results on isolation rates from infected patients. The team also focused on raising public awareness of scrub typhus as delayed diagnosis is strongly associated with morbidity and mortality.

The Newton Prize is part of the broader Newton Fund, which builds research and innovation partnerships with 18 partner countries to support their economic development and social welfare, and to develop their research and innovation capacity for long-term sustainable growth. It has a total UK Government investment of £735 million up until 2021, and each partner country provides matched funding and resources for every programme, making it an equitable partnership.

More than 150 Newton funded projects, fellowships or other awards applied for the Newton Prize from the eligible countries for this year – India, Malaysia, Thailand and Vietnam. There are 25 shortlisted applications in total and five Prizes of up to £200,000 will be awarded to each winner to be used to advance or develop existing Newton funded work. There will be two winners in India and one each in Malaysia, Thailand and Vietnam.

Newton Prize winners will be announced at award ceremonies held in each of the partner countries:

  • India – 1 November
  • Vietnam – 16 November
  • Thailand – 22 November
  • Malaysia – 28 November

The Minister for Universities, Science, Research and Innovation Jo Johnson will host a London event in early December to celebrate the Prize’s first year and announce the 2018 Newton Prize countries.

Professor Day is also Director of the Bangkok-based Mahidol-Oxford Tropical Medicine Research Unit (MORU). Established in 1979 as a research collaboration between Mahidol University, Oxford and Wellcome, MORU’s main office and labs are located within Mahidol’s Faculty of Tropical Medicine, with MORU Units, study sites and collaborations across Thailand, Asia and Africa.

The Newton Prize aims to incentivise researchers to participate in the Newton Fund as partners with the UK, and to work on the most important challenges facing Newton countries. The concept for the Newton Prize has been developed to demonstrate how UK partnerships with Newton countries are solving global challenges.

Further information is available on the Newton Fund website. Follow their Twitter feed for regular updates about the Newton Prize: @NewtonFund and #NewtonPrize.

Similar stories

World’s largest clinical trial for COVID-19 treatments expands internationally

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

OCGHR Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.